Developing targeted nanoparticle therapies for lupus nephritis
Core B - BWH Nanoparticle Core
['FUNDING_P01'] · BETH ISRAEL DEACONESS MEDICAL CENTER · NIH-11046580
This study is exploring new tiny treatments that can help people with lupus nephritis by delivering medicine directly to the kidneys, aiming to improve how well the treatment works while reducing side effects.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BETH ISRAEL DEACONESS MEDICAL CENTER (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11046580 on ClinicalTrials.gov |
What this research studies
This research focuses on creating advanced nanoparticle-based therapies aimed at improving treatment outcomes for patients with lupus nephritis (LN). By utilizing nanotechnology, the project seeks to enhance the delivery of immune therapeutics directly to the kidneys, where they are most needed, while minimizing systemic side effects. The approach involves targeting newly formed blood vessels in the kidneys to ensure that the therapeutic agents effectively suppress harmful immune responses. This innovative method aims to address the significant challenges and complications associated with current treatment regimens.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lupus nephritis who are seeking more effective treatment options.
Not a fit: Patients with lupus nephritis who are not responsive to immune therapeutics or those with contraindications to nanoparticle therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for lupus nephritis, reducing complications and improving patient outcomes.
How similar studies have performed: While there has been significant success in using nanotechnology for cancer treatments, the application of nanoparticle therapies specifically for lupus nephritis is still a novel approach.
Where this research is happening
BOSTON, UNITED STATES
- BETH ISRAEL DEACONESS MEDICAL CENTER — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ABDI, REZA — BETH ISRAEL DEACONESS MEDICAL CENTER
- Study coordinator: ABDI, REZA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy, cancer therapy, Cancer Treatment, cancer-directed therapy, Cancers